2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
August 02, 2019
Article
Mitchel Hoffman, MD, explains the use of surgery and neoadjuvant chemotherapy in ovarian cancer.
August 01, 2019
Article
Hye Sook Chon, MD, discusses the progress of maintenance therapy in ovarian cancer.
July 30, 2019
Article
Robert M. Wenham, MD, discusses frontline management strategies for patients with newly diagnosed advanced ovarian cancer as well as the complexities of maintenance therapy.
July 25, 2019
Video
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the plans for the CA045-001 trial, an international, multicenter study that is comparing bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.
July 09, 2019
Video
Nikhil Khushalani, MD, discusses the CA045-001 study, a phase III, randomized study that compared bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.
June 26, 2019
Video
Bijal Shah, MD, discusses the results of the phase I/II ZUMA-3 study, which looked at using KTE-X19, an anti-CD19 CAR T-cell therapy, to treat patients with relapsed/refractory acute lymphoblastic leukemia.
June 19, 2019
Video
Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses the rationale and design of a phase II study of TAS-102 (trifluridine/tipiracil; Lonsurf) in combination with ramucirumab (Cyramza) in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma (NCT03686488).
April 26, 2019
Video
Richard Kim, MD, assistant professor of oncology at University of South Florida College of Medicine, medical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses the potential of ramucirumab in the treatment of advanced hepatocellular carcinoma.
April 23, 2019
Video
Bijal D. Shah, MD, oncologist/hematologist, Moffitt Cancer Center, discusses ongoing trials in the field of mantle cell lymphoma (MCL).
April 19, 2019
Video
Bijal D. Shah, MD, associate member, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses challenges with developing mantle cell lymphoma clinical trials.
April 17, 2019
Video
Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses overcoming resistance to BTK inhibitors in the treatment of mantle cell lymphoma.
April 08, 2019
Video
Richard Kim, MD, assistant professor of oncology, University of South Florida College of Medicine, medical oncologist, Department of Gastrointestinal Oncology, Moffitt Cancer Center, discusses the role of frontline immunotherapy in patients with advanced hepatocellular carcinoma.
March 22, 2019
Article
Iman Imanirad, MD, discusses these trials in depth and their impact on patients with refractory metastatic colorectal cancer.
March 22, 2019
Video
Rutika Mehta, MD, MPH, gastrointestinal medical oncologist at Moffitt Cancer Center, discusses the use of immunotherapy in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma.
March 22, 2019
Article
Damian Laber, MD, provides a brief history of the trials that led to current frontline and second-line standards for patients with metastatic pancreatic cancer and shares his hope for the future of the treatment paradigm.
March 20, 2019
Article
Rutika Mehta, MD, MPH, discusses the current gastric cancer treatment landscape and sheds light on how emerging therapies could impact the paradigm.
March 19, 2019
Article
Dae Won Kim, MD, highlights recent advances in the neoadjuvant and adjuvant settings for patients with localized pancreatic cancer.
March 19, 2019
Article
Richard Kim, MD, discusses the therapeutic landscape of advanced hepatocellular carcinoma in light of recent findings and highlighted anticipated research in the field.
March 13, 2019
Article
Jonathan R. Strosberg, MD, sheds light on the latest developments made in the complex treatment paradigm of gastroenteropancreatic neuroendocrine tumors.
March 13, 2019
Video
Damian Laber, MD, hematologist/oncologist, senior member, Moffitt Cancer Center, discusses the PRODIGE 35-PANOPTIMOX trial in metastatic pancreatic cancer.